Tỷ lệ bạch cầu trước phẫu thuật xạ trị và điểm dự đoán Glasgow đã được điều chỉnh tiên đoán sự sống sót ở bệnh nhân di căn não của ung thư phổi không tế bào nhỏ

Soffietti R, Ruda R, Mutani R (2002) Management of brain metastases. J Neurol 249(10):1357–1369. https://doi.org/10.1007/s00415-002-0870-6 Patchell RA (2003) The management of brain metastases. Cancer Treat Rev 29(6):533–540 Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S, Committee EG (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. https://doi.org/10.1093/annonc/mdy275 Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70(2):510–514. https://doi.org/10.1016/j.ijrobp.2007.06.074 Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745–751. https://doi.org/10.1016/s0360-3016(96)00619-0 Weltman E, Salvajoli JV, Brandt RA, de Morais HR, Prisco FE, Cruz JC, de Oliveira Borges SR, Wajsbrot DB (2000) Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys 46(5):1155–1161. https://doi.org/10.1016/s0360-3016(99)00549-0 Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP (2017) Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol 3(6):827–831. https://doi.org/10.1001/jamaoncol.2016.3834 Mitsuya K, Nakasu Y, Kurakane T, Hayashi N, Harada H, Nozaki K (2017) Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis. J Neurosurg 127(2):433–437. https://doi.org/10.3171/2016.8.JNS16899 McMillan DC (2013) The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 39(5):534–540. https://doi.org/10.1016/j.ctrv.2012.08.003 Jin J, Hu K, Zhou Y, Li W (2017) Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis. PLoS ONE 12(9):e0184412. https://doi.org/10.1371/journal.pone.0184412 Mandaliya H, Jones M, Oldmeadow C, Nordman II (2019) Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res 8(6):886–894. https://doi.org/10.21037/tlcr.2019.11.16 Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89(6):1028–1030. https://doi.org/10.1038/sj.bjc.6601242 Gu X, Sun S, Gao XS, Xiong W, Qin S, Qi X, Ma M, Li X, Zhou D, Wang W, Yu H (2016) Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. Sci Rep 6:23893. https://doi.org/10.1038/srep23893 Gu XB, Tian T, Tian XJ, Zhang XJ (2015) Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep 5:12493. https://doi.org/10.1038/srep12493 Gatterbauer B, Hirschmann D, Eberherr N, Untersteiner H, Cho A, Shaltout A, Gobl P, Fitschek F, Dorfer C, Wolfsberger S, Kasprian G, Holler C, Frischer JM (2020) Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study. Cancer Med 9(11):4026–4036. https://doi.org/10.1002/cam4.3021 Frischer JM, Fraller A, Mallouhi A, Vogl UM, Baier F, Ertl A, Preusser M, Knosp E, Kitz K, Gatterbauer B (2016) Evaluation of dose-staged gamma knife radiosurgical treatment method for high-risk brain metastases. World Neurosurg 94:352–359. https://doi.org/10.1016/j.wneu.2016.07.038 Garassino MC, Gadgeel S, Esteban E, Felip E, Speranza G, Domine M, Hochmair MJ, Powell S, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Wei Z, Burke T, Pietanza MC, Rodriguez-Abreu D (2020) Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 21(3):387–397. https://doi.org/10.1016/S1470-2045(19)30801-0 Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB (2019) Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med 7(4):347–357. https://doi.org/10.1016/S2213-2600(18)30500-9 Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP (2016) The effect of gene alterations and tyrosine kinase inhibition on survival and cause of death in patients with adenocarcinoma of the lung and brain metastases. Int J Radiat Oncol Biol Phys 96(2):406–413. https://doi.org/10.1016/j.ijrobp.2016.06.006 Bowden G, Kano H, Caparosa E, Park SH, Niranjan A, Flickinger J, Lunsford LD (2015) Gamma knife radiosurgery for the management of cerebral metastases from non-small cell lung cancer. J Neurosurg 122(4):766–772. https://doi.org/10.3171/2014.12.JNS141111 Cannon NA, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H, Timmerman R (2015) Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol 10(2):280–285. https://doi.org/10.1097/JTO.0000000000000399 Xia H, Sun Z, Deng L, Zhu D, Wang D (2016) Prognostic significance of the preoperative lymphocyte to monocyte ratio in patients with stage I non-small cell lung cancer undergoing complete resection. Cancer Invest 34(8):378–384. https://doi.org/10.1080/07357907.2016.1213276 Chowdhary M, Switchenko JM, Press RH, Jhaveri J, Buchwald ZS, Blumenfeld PA, Marwaha G, Diaz A, Wang D, Abrams RA, Olson JJ, Shu HG, Curran WJ, Patel KR (2018) Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol 139(3):689–697. https://doi.org/10.1007/s11060-018-2914-5 Zhang L, Hu Y, Chen W, Tian Y, Xie Y, Chen J (2020) Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio is a predictor of the prognosis for brain metastases. J Neurooncol 147(3):691–700. https://doi.org/10.1007/s11060-020-03477-w Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444. https://doi.org/10.1038/nature07205 Lim JU, Yeo CD, Kang HS, Park CK, Kim JS, Kim JW, Kim SJ, Lee SH (2019) Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion. Sci Rep 9(1):4721. https://doi.org/10.1038/s41598-019-41289-9 Jiang T, Bai Y, Zhou F, Li W, Gao G, Su C, Ren S, Chen X, Zhou C (2019) Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. Lung Cancer 130:76–83. https://doi.org/10.1016/j.lungcan.2019.02.009 Sun H, Hu P, Shen H, Dong W, Zhang T, Liu Q, Du J (2015) Albumin and neutrophil combined prognostic grade as a new prognostic factor in non-small cell lung cancer: results from a large consecutive cohort. PLoS ONE 10(12):e0144663. https://doi.org/10.1371/journal.pone.0144663 Leung EY, Scott HR, McMillan DC (2012) Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol 7(4):655–662. https://doi.org/10.1097/JTO.0b013e318244ffe1 Proctor MJ, Morrison DS, Talwar D, Balmer SM, O’Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 104(4):726–734. https://doi.org/10.1038/sj.bjc.6606087 Fan H, Shao ZY, Xiao YY, Xie ZH, Chen W, Xie H, Qin GY, Zhao NQ (2016) Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer. J Cancer Res Clin Oncol 142(6):1285–1297. https://doi.org/10.1007/s00432-015-2113-0